Boston Trust Walden Corp Sells 113,077 Shares of Globus Medical, Inc. $GMED

Boston Trust Walden Corp reduced its stake in Globus Medical, Inc. (NYSE:GMED) by 8.3% during the 1st quarter, Holdings Channel reports. The firm owned 1,254,910 shares of the medical device company’s stock after selling 113,077 shares during the period. Globus Medical makes up 0.9% of Boston Trust Walden Corp’s holdings, making the stock its 17th biggest holding. Boston Trust Walden Corp’s holdings in Globus Medical were worth $108,123,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in GMED. Root Financial Partners LLC increased its holdings in shares of Globus Medical by 291.5% in the first quarter. Root Financial Partners LLC now owns 779 shares of the medical device company’s stock worth $67,000 after acquiring an additional 580 shares in the last quarter. Trust Investment Advisors acquired a new position in shares of Globus Medical in the 1st quarter valued at approximately $1,028,000. SMART Wealth LLC bought a new stake in Globus Medical during the 1st quarter worth approximately $273,000. Inspire Investing LLC increased its stake in Globus Medical by 234,962.5% during the 1st quarter. Inspire Investing LLC now owns 18,805 shares of the medical device company’s stock worth $1,620,000 after purchasing an additional 18,797 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its holdings in Globus Medical by 23.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 26,736 shares of the medical device company’s stock worth $2,304,000 after buying an additional 5,022 shares during the period. 95.16% of the stock is owned by institutional investors and hedge funds.

Globus Medical Stock Up 5.3%

Shares of NYSE GMED opened at $80.01 on Friday. The business’s 50 day moving average price is $82.38 and its two-hundred day moving average price is $87.17. The company has a market cap of $10.86 billion, a PE ratio of 18.61, a price-to-earnings-growth ratio of 1.57 and a beta of 0.95. Globus Medical, Inc. has a twelve month low of $51.79 and a twelve month high of $101.40.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. During the same period in the previous year, the company posted $0.68 EPS. The firm’s revenue for the quarter was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, research analysts anticipate that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Needham & Company LLC upped their target price on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Piper Sandler reduced their price objective on Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research report on Monday, June 15th. Wells Fargo & Company decreased their price objective on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Royal Bank Of Canada lifted their target price on Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Finally, Wall Street Zen cut Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $105.00.

Insiders Place Their Bets

In related news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 18.38% of the stock is owned by insiders.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.